Clinical trials: Seizure, Epileptic
Epilepsy
Subcutaneous Intersectional Short Pulse Stimulation in Epileptic Patients
A subgaleal electrode-based system combined with the novel intersectional short-pulse (ISP) stimulation was developed to enable non-invasive, high-intensity neuromodulation.
- Trial name
- NCT07041619
- Testing
- Intersection short-pulse (ISP) stimulation
- Where
- Hungary
- Volunteers
- 30 people
- Sponsor
- Semmelweis University
Epilepsy, Generalized, Helicobacter Pylori Infection
Helicobacter Pylori Eradication Therapy for Epileptic Children
Helicobacter pylori (H. pylori) infection is associated with several health problems. The role of H. pylori infection in epilepsy has been investigated in a few studies.
- Trial name
- NCT05297695
- Testing
- Triple therapy for H. pylori infection
- Where
- Egypt
- Volunteers
- 126 people
- Sponsor
- Sohag University
Dravet Syndrome, Lennox Gastaut Syndrome
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
- Trial name
- NCT03936777
- Testing
- ZX008 (Fenfluramine Hydrochloride)
- Where
- 71 sites in United States, Australia and 12 more
- Volunteers
- 412 people
- Sponsor
- Zogenix, Inc.
Epilepsy, Dravet Syndrome
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
- Trial name
- NCT02091375
- Testing
- GWP42003-P 20 mg/kg/day Dose
- Where
- 22 sites in United States, France and 2 more
- Volunteers
- 120 people
- Sponsor
- Jazz Pharmaceuticals
Seizures
Dosing of Levetiracetam (Keppra) in Neonates
The primary objective of this study is to determine the pharmacokinetic profile of a 50 mg/kg loading dose of intravenous levetiracetam (LEV) in term and late preterm infants with seizures.
- Trial name
- NCT01239212
- Testing
- levetiracetam
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Dravet Syndrome
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
EXPEDITION is a Phase 1/2 study in the UK to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet Syndrome aged 6 to < 48 months. The study follows and open-label, dose-escalation design.
- Trial name
- UK Only (NCT06283212)
- Testing
- ETX101
- Where
- 3 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Encoded Therapeutics
Lennox-Gastaut Syndrome
Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs
This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic…
- Trial name
- NCT01405053
- Testing
- Rufinamide, Any other approved Antiepileptic Drug
- Where
- 47 sites in United States, Canada and 5 more
- Volunteers
- 37 people
- Sponsor
- Eisai Inc.
Brain Neoplasm, Low Grade Glioma
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
This study investigates how seizures can vary over time with changes in low grade gliomas and its treatments. This study may help doctors find symptoms or triggers of seizures earlier than normal, and ultimately earlier care or…
- Conditions
- Brain Neoplasm, Low Grade Glioma, Seizure Disorder
- Trial name
- NCT04553757
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Epilepsy, Microbiota
EPIGUT: EPILEPSY AND GASTROINTESTINAL MICROBIOTA: UNDERSTANDING THERAPY RESPONSE
The goal of this observational study is to learn how the bacteria in the gut and mouth (called the microbiota) are linked to different types of epilepsy and how they may affect how well seizure medicines work.
- Conditions
- Epilepsy, Microbiota, Proteomics, Metabolomics
- Trial name
- EpiGUT (NCT07253701)
- Where
- 6 sites in Sweden
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Epilepsy
Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate
Zonisamide (Zonegran) and sodium valproate (Epilim) are both medicines approved to treat epilepsy. The purpose of this study is to find out the extent to which zonisamide may affect memory and concentration, compared to sodium…
- Trial name
- NCT00713622
- Testing
- Zonisamide, Sodium valproate
- Where
- 2 sites in Austria, Finland
- Volunteers
- 2 people
- Sponsor
- Eisai Limited
Temporal Lobe Epilepsy
Subcutaneous EEG in Epilepsy
The study is a two-phase study, which aims to explore the uses of a novel electrode type in detecting epileptic seizures. The electrode is designed for subcutaneous implantation with long-term monitoring in mind.
- Trial name
- NCT02946151
- Testing
- UNEEG implantable EEG electrode and data storage device
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Zealand University Hospital
Epilepsy
Acoustic Stimulation for Seizure Suppression
The objective of this study is to test the feasibility and physiological effect of low-frequency (1 Hz) acoustic stimulation delivered during nocturnal NREM sleep in epilepsy patients.
- Trial name
- NCT03198494
- Testing
- Acoustic 1Hz Stimulation
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- NYU Langone Health
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Biomarkers in Neurodegenerative Diseases
The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD)
- Trial name
- NCT04055532
- Testing
- Neuraceq
- Where
- United States
- Sponsor
- University of Minnesota
Epilepsy
Study on Migraine and Headache in Epileptic Patients
The purpose of this study is to collect data from patients who are diagnosed with epilepsy and are followed up in epilepsy clinics.
- Trial name
- NCT00642564
- Testing
- Observational study in Epileptic Patients
- Volunteers
- 955 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Seizures, Epilepsy
Reduction and Prevention of Seizure Occurrence From Exposure to Auditory Stimulation in Individuals With Neurological Handicaps
Neurologically-impaired individuals may have significant neurologic morbidity related to epilepsy and seizure disorders. Finding safe, noninvasive methods of decreasing seizures, and potentially reversing the epileptogenic…
- Trial name
- NCT01459692
- Testing
- Music Exposure
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Drug Resistant Epilepsy, Focal Seizure
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007
This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007.
- Trial name
- NCT06899230
- Testing
- iQ-007
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- iQure Australia Pty Ltd
Epilepsy, Encephalitis Autoimmune
Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology
Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of…
- Trial name
- NCT06388161
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shen Chun-Hong
Dravet Syndrome
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity
Dravet syndrome is characterized as a developmental encephalopathy resulting from mutations of SCN1A, the gene encoding the alpha subunit of the voltage-gated sodium channel Nav1.1.
- Trial name
- EXEDRA (NCT06371794)
- Testing
- skin punch biopsy
- Where
- Italy
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dravet Syndrome
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome
This study will assess how well the drug verapamil can improve control of seizures and dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome.
- Trial name
- NCT01607073
- Testing
- Verapamil
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Gillette Children's Specialty Healthcare
Absence Seizures, Absence Epilepsy
ECV - Epihunter Clinical Validation
The goal of this prospective study is to validate a wearable EEG seizure detection solution compared to video EEG. Subjects that undergo a clinical video EEG are asked to additionally wear a wearable EEG headband for up to 2…
- Trial name
- ECV (NCT04615442)
- Testing
- Epihunter
- Where
- 4 sites in United States, Belgium and 2 more
- Volunteers
- 102 people
- Sponsor
- Epihunter NV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.